CompletedPhase 3NCT01741532
Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)
Studying Pantothenate kinase-associated neurodegeneration
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ApoPharma
- Principal Investigator
- Fernando Tricta, MDApoPharma Inc.
- Intervention
- Deferiprone oral solution(drug)
- Enrollment
- 89 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2012 – 2017
Study locations (4)
- Children's Hospital & Research Center at Oakland, Oakland, California, United States
- Klinikum der Universität München, Munich, Germany
- Foundation Neurological Institute C. Besta, Milan, Italy
- Newcastle University Institute of Human Genetics, Newcastle upon Tyne, United Kingdom
Collaborators
Food and Drug Administration (FDA)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01741532 on ClinicalTrials.gov